Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model

OBJECTIVE: Continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) are main modalities for end stage renal disease (ESRD) patients, and those have been covered by National Health Insurance (NHI) scheme since 2014 in Indonesia. This study aims to update the cost-effectiveness model of...

Descripción completa

Detalles Bibliográficos
Autores principales: Putri, Septiara, Nugraha, Ryan R., Pujiyanti, Eka, Thabrany, Hasbullah, Hasnur, Hanifah, Istanti, Novita D., Evasari, Diah, Afiatin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724412/
https://www.ncbi.nlm.nih.gov/pubmed/36474238
http://dx.doi.org/10.1186/s13104-022-06252-4
_version_ 1784844409529958400
author Putri, Septiara
Nugraha, Ryan R.
Pujiyanti, Eka
Thabrany, Hasbullah
Hasnur, Hanifah
Istanti, Novita D.
Evasari, Diah
Afiatin
author_facet Putri, Septiara
Nugraha, Ryan R.
Pujiyanti, Eka
Thabrany, Hasbullah
Hasnur, Hanifah
Istanti, Novita D.
Evasari, Diah
Afiatin
author_sort Putri, Septiara
collection PubMed
description OBJECTIVE: Continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) are main modalities for end stage renal disease (ESRD) patients, and those have been covered by National Health Insurance (NHI) scheme since 2014 in Indonesia. This study aims to update the cost-effectiveness model of CAPD versus HD in Indonesia setting. RESULTS: Compared to HD, CAPD provides good value for money among ESRD patients in Indonesia. Using societal perspective, the total costs were IDR 1,348,612,118 (USD 95,504) and IDR 1,368,447,750 (USD 96,908), for CAPD and HD, respectively. The QALY was slightly different between two modalities, 4.79 for CAPD versus 4.22 for HD. The incremental cost-effectiveness ratio (ICER) yields savings of IDR 34,723,527/QALY (USD 2460). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-022-06252-4.
format Online
Article
Text
id pubmed-9724412
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97244122022-12-07 Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model Putri, Septiara Nugraha, Ryan R. Pujiyanti, Eka Thabrany, Hasbullah Hasnur, Hanifah Istanti, Novita D. Evasari, Diah Afiatin BMC Res Notes Research Note OBJECTIVE: Continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) are main modalities for end stage renal disease (ESRD) patients, and those have been covered by National Health Insurance (NHI) scheme since 2014 in Indonesia. This study aims to update the cost-effectiveness model of CAPD versus HD in Indonesia setting. RESULTS: Compared to HD, CAPD provides good value for money among ESRD patients in Indonesia. Using societal perspective, the total costs were IDR 1,348,612,118 (USD 95,504) and IDR 1,368,447,750 (USD 96,908), for CAPD and HD, respectively. The QALY was slightly different between two modalities, 4.79 for CAPD versus 4.22 for HD. The incremental cost-effectiveness ratio (ICER) yields savings of IDR 34,723,527/QALY (USD 2460). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-022-06252-4. BioMed Central 2022-12-06 /pmc/articles/PMC9724412/ /pubmed/36474238 http://dx.doi.org/10.1186/s13104-022-06252-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Note
Putri, Septiara
Nugraha, Ryan R.
Pujiyanti, Eka
Thabrany, Hasbullah
Hasnur, Hanifah
Istanti, Novita D.
Evasari, Diah
Afiatin
Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model
title Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model
title_full Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model
title_fullStr Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model
title_full_unstemmed Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model
title_short Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model
title_sort supporting dialysis policy for end stage renal disease (esrd) in indonesia: an updated cost-effectiveness model
topic Research Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724412/
https://www.ncbi.nlm.nih.gov/pubmed/36474238
http://dx.doi.org/10.1186/s13104-022-06252-4
work_keys_str_mv AT putriseptiara supportingdialysispolicyforendstagerenaldiseaseesrdinindonesiaanupdatedcosteffectivenessmodel
AT nugraharyanr supportingdialysispolicyforendstagerenaldiseaseesrdinindonesiaanupdatedcosteffectivenessmodel
AT pujiyantieka supportingdialysispolicyforendstagerenaldiseaseesrdinindonesiaanupdatedcosteffectivenessmodel
AT thabranyhasbullah supportingdialysispolicyforendstagerenaldiseaseesrdinindonesiaanupdatedcosteffectivenessmodel
AT hasnurhanifah supportingdialysispolicyforendstagerenaldiseaseesrdinindonesiaanupdatedcosteffectivenessmodel
AT istantinovitad supportingdialysispolicyforendstagerenaldiseaseesrdinindonesiaanupdatedcosteffectivenessmodel
AT evasaridiah supportingdialysispolicyforendstagerenaldiseaseesrdinindonesiaanupdatedcosteffectivenessmodel
AT afiatin supportingdialysispolicyforendstagerenaldiseaseesrdinindonesiaanupdatedcosteffectivenessmodel

Ejemplares similares